EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial

Yuan Cheng, Jinguo Xia, Yongquan Chi, Jianhua Rao, Feng Cheng, CLEAP China Liver Cancer Study Group Young Investigators (CLEAP)

BMJ Open · 2026

DOI: 10.1136/bmjopen-2025-101101 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BMJ Open, 2026. Verfasst von Yuan Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Bile Duct Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the “Bottleneck" Technical Breakthrough Talent Support Special Project of Jiangsu Province’s "333 High-Level Talents”, the Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project, the Beijing Chen Jumei Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Intrahepatic cholangiocarcinoma (ICC) has a high recurrence rate after curative surgery, with no standard neoadjuvant therapy. Hepatic arterial infusion chemotherapy (HAIC) has shown efficacy in locally advanced ICC, while immune checkpoint inhibitors and anti-angiogenic agents have demonstrated promising response rates. The NEO-ERA-01 study evaluates the feasibility of neoadjuvant HAIC-GEMOX plus lenvatinib and Adebrelimab in high-risk resectable ICC. Methods and analysis NEO-ERA-01 is a prospective, multicentre, phase II trial using Simon’s two-stage design. Thirty patients with histologically confirmed resectable ICC and high-risk recurrence factors will be enrolled in China. Neoadjuvant therapy consists of HAIC-GEMOX (gemcitabine 800 mg/m², oxaliplatin 85 mg/m² every 3 weeks), lenvatinib (8 mg/day from Day 5) and Adebrelimab (1200 mg on Day 3, every 3 weeks) for 2–4 cycles. Surgery eligibility will be assessed post-treatment. Resected patients will receive adjuvant capecitabine (1250 mg/m² two times per day on Days 1–14, every 3 weeks) and Adebrelimab (1200 mg on Day 1, every 3 weeks) for 6 months. The primary endpoint is the completion rate of study treatment. Secondary endpoints include safety, R0 resection rate, response rate, event-free survival, disease-free survival and overall survival. Exploratory endpoints include immune microenvironment and biomarker analysis. Ethics and dissemination The study is approved by the ethics committee of all sites and follows the Declaration of Helsinki and good clinical practice guidelines. Results will be disseminated via peer-reviewed publications and conferences. Trial registration number NCT06208462 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsNeoadjuvant TherapyNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedHumansQuinolinesPhenylurea CompoundsInfusions, Intra-ArterialFeasibility StudiesProspective StudiesGemcitabineDeoxycytidineFemaleOxaliplatinHepatic ArteryClinical Trials, Phase II as TopicMulticenter Studies as TopicChinaMaleMiddle Aged

Stichwörter der Autor:innen

Clinical ProtocolsHepatobiliary diseaseHepatology

Substanzen

QuinolinesPhenylurea CompoundslenvatinibGemcitabineDeoxycytidineOxaliplatinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
  • Hepatobiliary Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Nanjing Medical University, Nanjing, Jiangsu, China.
  • Hepatobiliary Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China docchengfeng@njmu.edu.cn raojh@njmu.edu.cn.

Förderung

  • the “Bottleneck" Technical Breakthrough Talent Support Special Project of Jiangsu Province’s "333 High-Level Talents”
  • the Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project
  • the Beijing Chen Jumei Foundation
  • Primary Health Care Foundation of China——JINGRUI Liver Cancer Young Investigators Research and innovation capacity Building Public Welfare Project
  • International Scientific Exchange Foundation of China

Zitieren

APA

Cheng, Y., Xia, J., Chi, Y., Rao, J., Cheng, F., & CLEAP China Liver Cancer Study Group Young Investigators (CLEAP) (2026). Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial. BMJ Open. https://doi.org/10.1136/bmjopen-2025-101101

Vancouver

Cheng Y, Xia J, Chi Y, Rao J, Cheng F, CLEAP China Liver Cancer Study Group Young Investigators (CLEAP). Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial. BMJ Open. 2026. doi:10.1136/bmjopen-2025-101101

BibTeX
@article{Cheng2026,
  author = {Cheng, Yuan and Xia, Jinguo and Chi, Yongquan and Rao, Jianhua and Cheng, Feng and CLEAP China Liver Cancer Study Group Young Investigators (CLEAP), CLEAP China Liver Cancer Study Group Young Investigators (CLEAP)},
  title = {Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial},
  journal = {BMJ Open},
  year = {2026},
  doi = {10.1136/bmjopen-2025-101101}
}
Kostenlos starten →